Cost-effectiveness of replacing NSAIDs with coxibs: Diclofenac and celecoxib in rheumatoid arthritis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 3, 2002, Pages 229-241

  Kristiansen, Ivar Sønbø ^a   Kvien, Tore Kristian ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Celecoxib; Cost effectiveness; Cost utility; Coxibs; Economics; NSAIDs; Rheumatoid arthritis; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; ROFECOXIB;

AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; NORWAY; PRESCRIPTION; REVIEW; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY;

EID: 0036079242     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.3.229     Document Type: Review

References (62)

1. The relative gastrointestinal toxicity of the nonsteroidal anti inflammatory drugs
2. Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response
3. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
4. Epidemiology of NSAID induced gastrointestinal complications
5. Non-steroidal anti-inflammatory drugs: Back to the future
6. Cyclooxygenase-2 selective inhibitors: Panacea or flash in the pan?
7. COX-1-sparing NSAIDs - Is the enthusiasm justified?
8. The classification of cyclooxygenase inhibitors
9. COX-2 inhibitors
10. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
11. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of platelet effects
12. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
13. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
14. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of platelet effects
15. Randomised double-blind comparison of celecoxib versus diclofenac in long-term management of rheumatoid arthritis
16. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
17. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
18. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
19. Reporting of 6-month vs. 12-month data in a clinical trial of celecoxib
20. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
21. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis
22. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland
23. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada
24. The Swedish ACCES model: Predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis
25. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway
26. Incremental cost-effectiveness analysis comparing rofecoxib with non-selective NSAIDs in osteoarthritis
27. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis
28. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis
29. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs
30. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models
31. Assessing and understanding patient risk
32. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
33. Symptoms in patients with peptic ulcer and hematemesis and/or melena related to the use of non-steroid anti-inflammatory drugs
34. Age-related mortality in patients treated endoscopically for bleeding peptic ulcer
35. Perforated peptic ulcer. Determinants of morbidity and mortality
36. Mortality and perforated peptic ulcer: A case for risk stratification in elderly patients
37. Perforated peptic ulcer over 56 years. Time trends in patients and disease characteristics
38. Factors influencing mortality in patients with bleeding ulcer. Review of 7 years' experience preceding therapeutic endoscopy
39. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
40. Performance of the Norwegian SF-36 health survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures
41. A table of values for cost-effectiveness analysis in healthcare (in Norwegian: Veiledende verditall for kostnad-nytte-analyser av helsetjenester)
42. Health status index models for use in resource allocation decisions. A critical review in the light of observed preferences for social choice
43. Social evaluation of healthcare versus personal evaluation of health states: Evidence on the validity of four health state scaling instruments using Norwegian and Australian surveys
44. Individual utilities are inconsistent with rationing choices
45. The person-trade-off approach to valuing healthcare programs
46. Survival and cause of death in rheumatoid arthritis: A 25-year prospective follow-up
47. Survival, prognosis and causes of death in rheumatoid arthritis
48. Length of life and cause of death in rheumatoid arthritis
49. Increased mortality among persons with rheumatoid arthritis but where RA does not appear on death certificate
50. Epidemiology of rheumatoid arthritis in Rochester, Minnesota: A study of incidence, prevalence and mortality
51. NSAIDS and selective COX-2 inhibitors: Competition between gastroprotection and cardioprotection
52. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study
53. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
54. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac
55. Celecoxib and the incidence of clinically significant upper gastrointestinal events